CN103408557A - Indolizidine alkaloid as well as preparation method and application thereof - Google Patents
Indolizidine alkaloid as well as preparation method and application thereof Download PDFInfo
- Publication number
- CN103408557A CN103408557A CN2013103629769A CN201310362976A CN103408557A CN 103408557 A CN103408557 A CN 103408557A CN 2013103629769 A CN2013103629769 A CN 2013103629769A CN 201310362976 A CN201310362976 A CN 201310362976A CN 103408557 A CN103408557 A CN 103408557A
- Authority
- CN
- China
- Prior art keywords
- ifb
- indolizidine
- mould
- fermented liquid
- column chromatography
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- HAJKHJOABGFIGP-UHFFFAOYSA-N indolizidine Chemical class C1CCCN2CCCC21 HAJKHJOABGFIGP-UHFFFAOYSA-N 0.000 title claims abstract description 24
- 229930005307 indolizidine alkaloid Natural products 0.000 title claims abstract description 19
- 238000002360 preparation method Methods 0.000 title claims abstract description 8
- 239000007788 liquid Substances 0.000 claims abstract description 14
- 230000003115 biocidal effect Effects 0.000 claims abstract description 9
- 239000003814 drug Substances 0.000 claims abstract description 7
- 238000000855 fermentation Methods 0.000 claims abstract description 4
- 230000004151 fermentation Effects 0.000 claims abstract description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 24
- 150000001875 compounds Chemical class 0.000 claims description 10
- 239000000284 extract Substances 0.000 claims description 10
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 6
- 238000010898 silica gel chromatography Methods 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- 239000000706 filtrate Substances 0.000 claims description 4
- XELZGAJCZANUQH-UHFFFAOYSA-N methyl 1-acetylthieno[3,2-c]pyrazole-5-carboxylate Chemical compound CC(=O)N1N=CC2=C1C=C(C(=O)OC)S2 XELZGAJCZANUQH-UHFFFAOYSA-N 0.000 claims description 4
- 239000000287 crude extract Substances 0.000 claims description 3
- 238000010828 elution Methods 0.000 claims description 3
- 238000003810 ethyl acetate extraction Methods 0.000 claims description 3
- 229940041514 candida albicans extract Drugs 0.000 claims description 2
- 238000013375 chromatographic separation Methods 0.000 claims description 2
- 238000004587 chromatography analysis Methods 0.000 claims description 2
- 238000004440 column chromatography Methods 0.000 claims description 2
- 239000012153 distilled water Substances 0.000 claims description 2
- 230000011218 segmentation Effects 0.000 claims description 2
- 239000012138 yeast extract Substances 0.000 claims description 2
- 229930006000 Sucrose Natural products 0.000 claims 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims 1
- 239000005720 sucrose Substances 0.000 claims 1
- 241000223208 Curvularia Species 0.000 abstract description 3
- 239000003242 anti bacterial agent Substances 0.000 abstract description 3
- 229940079593 drug Drugs 0.000 abstract description 3
- 241000233866 Fungi Species 0.000 abstract description 2
- 230000002401 inhibitory effect Effects 0.000 abstract description 2
- 150000002611 lead compounds Chemical class 0.000 abstract description 2
- 230000000813 microbial effect Effects 0.000 abstract description 2
- 241001604174 Genyonemus lineatus Species 0.000 abstract 1
- 230000000968 intestinal effect Effects 0.000 abstract 1
- 239000000463 material Substances 0.000 abstract 1
- 230000001988 toxicity Effects 0.000 abstract 1
- 231100000419 toxicity Toxicity 0.000 abstract 1
- 239000013078 crystal Substances 0.000 description 11
- 238000005481 NMR spectroscopy Methods 0.000 description 9
- 238000000034 method Methods 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 5
- 241000223211 Curvularia lunata Species 0.000 description 5
- 229940125782 compound 2 Drugs 0.000 description 5
- 230000003103 anti-anaerobic effect Effects 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 230000003595 spectral effect Effects 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- 241001417494 Sciaenidae Species 0.000 description 3
- 229940125904 compound 1 Drugs 0.000 description 3
- 229940126214 compound 3 Drugs 0.000 description 3
- 229910002804 graphite Inorganic materials 0.000 description 3
- 239000010439 graphite Substances 0.000 description 3
- 238000002114 high-resolution electrospray ionisation mass spectrometry Methods 0.000 description 3
- 230000005855 radiation Effects 0.000 description 3
- 125000006850 spacer group Chemical group 0.000 description 3
- 241001148471 unidentified anaerobic bacterium Species 0.000 description 3
- FRXSZNDVFUDTIR-UHFFFAOYSA-N 6-methoxy-1,2,3,4-tetrahydroquinoline Chemical compound N1CCCC2=CC(OC)=CC=C21 FRXSZNDVFUDTIR-UHFFFAOYSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 241000186041 Actinomyces israelii Species 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- 241000606215 Bacteroides vulgatus Species 0.000 description 2
- 241001558166 Curvularia sp. Species 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000002538 fungal effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000007791 liquid phase Substances 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000003643 water by type Substances 0.000 description 2
- 241000251468 Actinopterygii Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241000250937 Pennahia argentata Species 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 241000191992 Peptostreptococcus Species 0.000 description 1
- 241000192035 Peptostreptococcus anaerobius Species 0.000 description 1
- 241000192033 Peptostreptococcus sp. Species 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 241000194022 Streptococcus sp. Species 0.000 description 1
- HJLSLZFTEKNLFI-UHFFFAOYSA-N Tinidazole Chemical compound CCS(=O)(=O)CCN1C(C)=NC=C1[N+]([O-])=O HJLSLZFTEKNLFI-UHFFFAOYSA-N 0.000 description 1
- 241001148134 Veillonella Species 0.000 description 1
- 241001148135 Veillonella parvula Species 0.000 description 1
- DPDMMXDBJGCCQC-UHFFFAOYSA-N [Na].[Cl] Chemical compound [Na].[Cl] DPDMMXDBJGCCQC-UHFFFAOYSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 238000004500 asepsis Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- WORJEOGGNQDSOE-UHFFFAOYSA-N chloroform;methanol Chemical compound OC.ClC(Cl)Cl WORJEOGGNQDSOE-UHFFFAOYSA-N 0.000 description 1
- 229940121657 clinical drug Drugs 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229930000044 secondary metabolite Natural products 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229960005053 tinidazole Drugs 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
Images
Landscapes
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The invention the technical field of microbial engineering, and particularly relates to an indolizidine alkaloid extracted from a liquid fermented material of white croaker intestinal fungi IFB-Z10 (Curvulariasp.) as well as a preparation method and application thereof. The indolizidine alkaloid disclosed by the invention is obtained by being separated and purified from the fermentation liquor of curvularia IFB-Z10 sourced from oceans, has a very high inhibiting effect on clinical anaerobion without toxicity on cells, thereby being used for producing the lead compound as an antibiotic and applied to preparing an antibiotic drug.
Description
One technical field
The invention belongs to the microbial engineering field, be specifically related to the sp. from white Chinese croaker enteron aisle fungi IFB-Z10(Curvularia) liquid fermentate the class Indolizidine alkaloid that extracts and its preparation method and application.
Two background technologies
Along with the continuous discovery of environmental microorganism, more and more difficult from its secondary metabolite, finding skeleton novelty or the significant microbiotic of biological activity.In recent years, the researchist has invested sight the oceanic resources with great potential more, and has found therefrom that a lot of skeletons are novel or had the medicine source molecule of notable biological activity, for further research new antibiotic molecule is laid a good foundation.At present, the phenomenon of abuse of antibiotics grows in intensity clinically, has caused the generation of a lot of pathogenic bacteria of drug-resistant, and especially so-called superbacteria, even also appearred in drug-resistant bacteria.Therefore traditional microbiotic has seemed helpless, and the urgent hope of scientist can be found a kind of novel antibiotic molecule, tackles these clinical drug-resistant bacterial strains, thereby fundamentally removes patient's misery.
Three summary of the invention
The present invention is from the enteron aisle fungal component Curvularia fungi IFB-Z10(Curvularia sp. of marine fishes white Chinese croaker (Argyrosomus argentatus)) liquid fermentate extract the Indolizidine alkaloid that a class has remarkable inhibition Clinical Anaerobic Bacteria activity.
The problem that the present invention need to solve is:
1. provide a class to have clinical anaerobism pathogenic bacteria and suppress active Indolizidine Alkaloid.
2. a kind of method for preparing the Indolizidine Alkaloid is provided.
3. the application of Curvularia lunata Indolizidine Alkaloid in suppressing the Clinical Anaerobic Bacteria medicine.
Technical scheme of the present invention:
Curvularia lunata of the present invention is drawn from invention patent " a kind of curved spore mould and the alkaloidal preparation method and application of Indolizidine, patent No. ZL201110105504.6 ", and Curvularia lunata Indolizidine alkaloid of the present invention has following structural formula:
The single crystal structure figure of Curvularia lunata Indolizidine alkaloid Curvulamines A-C (1-3) is shown in Figure of description 1-3.
Curvularia lunata Indolizidine alkaloid preparation method, comprise the steps:
1. will be from fresh white Chinese croaker, separating, the thalline piece of the mould IFB-Z10 of curved spore that purifying obtains is inoculated in improvement Cha Shi substratum, on shaking table, 150rpm, 28 ℃ of condition bottom fermentations 12 days;
2. step 1 gained fermented liquid is filtered through gauze, filtrate is used ethyl acetate extraction, the dry black crude extract F that obtains of vacuum concentration;
3. step 2 gained medicinal extract F is carried out to the silica gel column chromatography segmentation, adopt chloroform/methanol gradient elution: 100:0,100:1,100:2,100:4,100:8,100:16, obtain 6 wash-out part F1-F6;
4. to medicinal extract F1, F2 and F4 adopt silica gel column chromatography, anti-phase C-18 column chromatography and Sephadex LH-20 chromatographic separation purifying to obtain containing the position F1-1 of three new compounds, F2-2 and F4-2 repeatedly;
5.F1-1 F2-2 and F4-2 prepare compound 1-3 through high pressure lipuid chromatography (HPLC) [chromatographic column: ODS-2Hypersil columns (5 μ, 250 * 10mm)].
Indolizidine alkaloid of the present invention has the effect of remarkable inhibition Clinical Anaerobic Bacteria, and does not have cytotoxicity, therefore can be used as a kind of microbiotic of novelty, and is applied in preparing antibiotic medicine.
Compared with prior art, the present invention has following outstanding advantages:
1. the Indolizidine alkaloid of the present invention compound that is the skeleton novelty, can be prepared into new antibiotic or lead compound, overcomes the shortcoming of existing antibiotic resistance.
2. Indolizidine alkaloid of the present invention can utilize microorganism to carry out liquid fermenting production, simple process, and the cycle is short, and cost is low, originates guaranteed.
The accompanying drawing explanation
Fig. 1 is the single crystal structure figure (comprising a methanol molecules) of compound 1.
Fig. 2 is the single crystal structure figure of compound 2.
Fig. 3 is the single crystal structure figure of compound 3.
Embodiment
By specific embodiment given below, can further understand the present invention.But they are not limitation of the invention.
Embodiment 1: the liquid fermenting mould IFB-Z10(Curvularia sp. of the curved spore of marine source)
The mould IFB-Z10 of curved spore of activation marine source, fresh thalline piece is inoculated in the 1000ml Erlenmeyer flask, every bottle of improvement Cha Shi substratum that contains 400ml, inoculation 5-6 bottle is on shaking table, under 150rpm, 28-30 ℃ condition, cultivate 3 days as seed liquor, then the inoculum size with 20ml was inoculated in seed liquor in the 1000ml Erlenmeyer flask of the improvement Cha Shi substratum that contains 400ml, 150rpm, 28-30 ℃ of condition bottom fermentation 12 days.
Embodiment 2: the alkaloidal extraction of Indolizidine with separate
In embodiment 1, the gained fermented liquid filters through gauze, and filtrate is used ethyl acetate extraction, the dry black crude extract F that obtains of vacuum concentration.Medicinal extract F is carried out to silica gel column chromatography, adopt chloroform/methanol gradient elution: 100:0,100:1,100:2,100:4,100:8,100:16, obtain 6 wash-out part F1-F6.Then medicinal extract F1 is carried out to Sephadex LH-20 separation with chloroform-methanol (v/v1:1), obtain F1-1, then recrystallization obtains compound 1 in methyl alcohol; (sherwood oil/acetone=10:1 → 1:1) obtains F2-2 to medicinal extract F2, then through partly preparing high-pressure liquid phase, and [chromatographic column: ODS-2Hypersil columns (5 μ, 250 * 10mm)] obtains compound 3 through silica gel column chromatography; Medicinal extract F4 obtains F4-2 through Sephadex LH-20 and ODS-A reverse phase silica gel (AA12S50) purifying, then by partly preparing high-pressure liquid phase [chromatographic column: ODS-2Hypersil columns (5 μ, 250 * 10mm)], prepares compound 2;
Embodiment 3: the alkaloidal Structural Identification of Indolizidine
The mass spectrum, nuclear magnetic resonance spectrum, X-ray single crystal diffraction that the alkaloidal structure of Indolizidine is based on them analyzed Analysis deterrmination.
Spectral data is as follows:
Curvulamine?A(1):yellow?needle;[α]
28 D-265(c0.03MeOH);UV(MeOH);λ
max(logε)230(3.6),297(3.7)nm;IR(KBr)ν
max:3416,2969,1644,1415,759cm
-1;HRESIMS:m/z:347.1725[M+Na]
+(calcd?for?C
20H
24N
2O
2Na
+,347.1730);
1H?and
13C?NMR?see?table1.
Curvulamine?B(2):yellow?solid;[α]
28 D-181.7(c0.09MeOH);UV(MeOH)λ
max(logε)231(3.9)nm;IR(KBr)ν
max:3491,2925,1417,1023,759cm
-1;HRESIMS:m/z:365.1846[M+Na]
+(calcd?for?C
20H
26N
2O
3Na
+,365.1841);
1H?and
13C?NMR?see?table2.
Curvulamine?C(3):yellow?solid;[α]
28 D-148.7(c0.08MeOH);UV(MeOH)λ
max(logε)227(3.7)nm;IR(KBr)ν
max:3502,2946,1508,1421,1035,763cm
-1;HRESIMS:m/z:395.1956[M+Na]
+(calcd?for?C
21H
28N
2O
4Na
+,395.1947);
1H?and
13C?NMR?see?table3.
Table 1.curvulamine A (1) NMR data (500MHz)
Table1.NMR?spectral?data?of?curvulamine?A(1)
Table 2.curvulamine B (2) NMR data (500MHz)
Table2.NMR?spectral?data?of?curvulamine?B(2)
asignals?overlapped.
Table 3.curvulamine C (3) NMR data (500MHz)
Table3.NMR?spectral?data?of?curvulamine?C(3)
S: unimodal, d: doublet, t: triplet, dd: quartet, br: broad peak
The X-ray single crystal diffraction of compound 1 is analyzed: C
20H
26N
2O
3, M342.43, spacer is P2 (1) 2 (1) 2 (1), unit cell parameters a=7.2482 (1), b=13.3145 (1), c=20.2206 (2)
Unit cell volume
Molecule number Z=4 in structure cell.R and wR value are respectively 0.0384,0.1130.With CuK α radiation, graphite monochromator.Use the ω scan mode, obtain 6495 of independent point diffractions.On microcomputer, parse the single crystal structure (seeing accompanying drawing 1) of compound 1 by direct method (SHELXS-97).
The X-ray single crystal diffraction of compound 2 is analyzed: C
20H
26N
2O
3, M342.43, spacer is C222 (1), unit cell parameters a=10.0414 (2), b=16.4683 (4),
α=β=γ=90.00 °; Unit cell volume
Molecule number Z=8 in structure cell.R and wR value are respectively 0.0422,0.1186.With CuK α radiation, graphite monochromator.Use the ω scan mode, obtain 10898 of independent point diffractions.On microcomputer, parse the single crystal structure (seeing accompanying drawing 2) of compound 2 by direct method (SHELXS-97).
The X-ray single crystal diffraction of compound 3 is analyzed: C
21H
28N
2O
4, M372.45, spacer is C222 (1), unit cell parameters a=11.5101 (1), b=14.4654 (2),
α=β=γ=90.00 °; Unit cell volume
Molecule number Z=8 in structure cell.R and wR value are respectively 0.0556,0.2084.With CuK α radiation, graphite monochromator.Use the ω scan mode, obtain 5567 of independent point diffractions.On microcomputer, parse the single crystal structure (seeing accompanying drawing 3) of compound 2 by direct method (SHELXS-97).
Embodiment 4:MIC method is measured compound 1-3 anti-anaerobic activity
1) preparation of substratum
The PDA substratum: potato 200g, be chopped into fourth, add water boil 30min, with gauze elimination residue, filtrate adds water to 1000mL, adds 20g agar, heat fused, then add 20g glucose, packing after dissolving, 121 ℃ of sterilizing 20min; Screening for Active antifungal compound.
LB substratum: peptone 5g, yeast extract paste 15g, sodium-chlor 5g, agar 20g, distilled water 1000mL, (PH7.0 ± 0.2); For bacteria culture, preserve and screening active ingredients.
2) adopt micro-dilution method (96 well plate method) to carry out the mensuration of anti-microbial activity
With the dilution of the micropore at the bottom of 12 * 8 96 U-shaped holes, hole plate, measure, every row 12 holes, the 1-8 hole respectively adds the liquid of 50 μ L gradient concentrations, and (compound sample 0.5mg adds the DMSO hydrotropy of 50 μ L, be dissolved in the 1mL sterilized water, be made into the liquid of initial concentration 500 μ g/mL, each micropore first adds the sterilized water of 50 μ L, adopts the doubling dilution gradient dilution, is made into series concentration).9th, 10 holes add 500 μ L sterilized waters as negative control, then in the 1-10 hole, add respectively the 50 μ L bacterium liquid (10 that diluted concentration
5Individual bacterium or fungal spore/mL).The 11st hole, 12 holes add respectively 100 μ L2.5%DMSO solution and 100 μ L sterilized waters as blank, after the vibration of micropore dilution plate mixes, are placed in 37 ℃ and cultivate 18-24h.
Visual inspection: observations under the light source of black background is being arranged, having the hole of bacteria growing to be the diffuse type muddiness or clasp sample precipitation is arranged at bottom, the contained minimum sample concentration in the hole of asepsis growth is the minimum inhibitory concentration MIC of this sample.
Anti-anaerobic activity test result (table 4) shows: compound 1-3 can optionally suppress clinical bacterium Veillonella (Veillonella parvula), Actinomyces Israeli (Actinomyces israelii), streptococcus anaerobius (Streptococcus sp.), bacteroides vulgatus (Bacteroides vulgatus) and peptostreptococcus (Peptostreptococcus sp.).
The anti-anaerobic activity of table 4. compound curvulamies
aThe positive control tinidazole
Above results suggest, Indolizidine alkaloid curvulamines A-C (1-3) has very strong anti-anaerobic activity and has certain selectivity, and therefore Indolizidine alkaloid of the present invention can be developed into new antibiotic.
Claims (3)
1. Indolizidine alkaloid prepared by the mould IFB-Z10 fermented liquid of curved spore, its structure is:
2. the alkaloidal preparation method of Indolizidine for preparing of the mould IFB-Z10 fermented liquid of curved spore according to claim 1 is characterized in that consisting of following steps:
1). the mould IFB-Z10 of curved spore activated is inoculated in improvement Cha Shi substratum, and it consists of: sucrose 30g, yeast extract paste 1.0g, NaNO
33.0g, KCl0.5g, K
2HPO
41.0g, MgSO
47H
2O0.5g, FeSO
47H
2O0.01g, 1L distilled water, then be placed on shaking table, 150rpm, 28 ℃ of condition bottom fermentations 12 days;
2). step 1 gained fermented liquid is filtered through gauze, and filtrate is used ethyl acetate extraction, the dry black crude extract F that obtains of vacuum concentration;
3). F carries out the silica gel column chromatography segmentation to step 2 gained medicinal extract, adopts chloroform/methanol gradient elution: 100:0,100:1,100:2,100:4,100:8,100:16, obtain 6 wash-out part F1-F6;
4). to medicinal extract F1, F2 and F4 adopt silica gel column chromatography, anti-phase C-18 column chromatography and Sephadex LH-20 chromatographic separation purifying to obtain containing the position F1-1 of three compounds, F2-2 and F4-2 repeatedly;
5) .F1-1, F2-2 and F4-2, through high pressure lipuid chromatography (HPLC), prepare compound 1-3, and chromatographic column is: ODS-2Hypersil columns.
3. the application of Indolizidine alkaloid in preparing antibiotic medicine that prepare of the mould IFB-Z10 fermented liquid of the described curved spore of claim 1.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310362976.9A CN103408557B (en) | 2013-08-19 | 2013-08-19 | Indolizidine alkaloid as well as preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310362976.9A CN103408557B (en) | 2013-08-19 | 2013-08-19 | Indolizidine alkaloid as well as preparation method and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103408557A true CN103408557A (en) | 2013-11-27 |
| CN103408557B CN103408557B (en) | 2015-04-29 |
Family
ID=49601613
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310362976.9A Expired - Fee Related CN103408557B (en) | 2013-08-19 | 2013-08-19 | Indolizidine alkaloid as well as preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103408557B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108822116A (en) * | 2018-06-04 | 2018-11-16 | 南京中医药大学 | Indole alkaloid with anti-tumor activity and its preparation method and application |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007046113A2 (en) * | 2005-10-18 | 2007-04-26 | Panacea Biotec Ltd. | Novel pharmaceutical composition comprising alkaloid and process thereof |
| CN101019539A (en) * | 2007-02-27 | 2007-08-22 | 南开大学 | Interacting composition possessing activity of resisting tobacco mosaic virus |
| CN102329735A (en) * | 2011-04-27 | 2012-01-25 | 南京大学 | Method for preparing curvularin and indolizidine alkaloid and application |
| CN103073527A (en) * | 2013-01-31 | 2013-05-01 | 南京大学 | Diterpene Libertellenone G and preparation method and use thereof |
-
2013
- 2013-08-19 CN CN201310362976.9A patent/CN103408557B/en not_active Expired - Fee Related
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007046113A2 (en) * | 2005-10-18 | 2007-04-26 | Panacea Biotec Ltd. | Novel pharmaceutical composition comprising alkaloid and process thereof |
| CN101019539A (en) * | 2007-02-27 | 2007-08-22 | 南开大学 | Interacting composition possessing activity of resisting tobacco mosaic virus |
| CN102329735A (en) * | 2011-04-27 | 2012-01-25 | 南京大学 | Method for preparing curvularin and indolizidine alkaloid and application |
| CN103073527A (en) * | 2013-01-31 | 2013-05-01 | 南京大学 | Diterpene Libertellenone G and preparation method and use thereof |
Non-Patent Citations (2)
| Title |
|---|
| 刘振佳: "菲并吲哚里西啶类生物碱13a-(s)-去氧娃儿藤宁的抗肿瘤作用及机制研究", 《北京协和医学院 中国医院科学院 博士学位论文》 * |
| 胡申才等，: "海洋微生物及其产生的生物活性物质的研究进展", 《第三届海洋高技术论坛》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108822116A (en) * | 2018-06-04 | 2018-11-16 | 南京中医药大学 | Indole alkaloid with anti-tumor activity and its preparation method and application |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103408557B (en) | 2015-04-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101591288B (en) | Cytochalasin compounds and preparation method and application thereof | |
| CN102311981B (en) | Method for preparing and purifying prodigiosin | |
| CN101974464A (en) | Streptomyces and process for preparing antimycin antibiotics by fermentation using same | |
| CN103360351A (en) | Isopimarane diterpenoid compounds and application thereof | |
| CN106432168A (en) | Rhizophorales B.sexangulavar.rhynchopetala endophytic fungi-based vibrio resistant active compound and preparation method thereof | |
| CN102746376A (en) | Cyclopeptide antibiotics and preparation method thereof and application of cylopeptide antibiotics in preparation of antibacterial agents | |
| CN102030753B (en) | Prenylated indole alkaloids and preparation method and application thereof | |
| CN106967024A (en) | A kind of α pyrone derivatives and its preparation method and application | |
| CN101720772A (en) | Macrolide composition for preventing and controlling fungal disease of crop and preparation process thereof | |
| CN103408557B (en) | Indolizidine alkaloid as well as preparation method and application thereof | |
| CN101892181B (en) | Streptoseomycin and preparation method and application thereof | |
| CN104804071B (en) | A kind of depside peptides and its preparation method and application | |
| CN105399721B (en) | Noval chemical compound and preparation method thereof and the application in antibacterial antineoplastic is prepared | |
| CN102051394A (en) | Preparation method and application of sulfo-diketopiperazine compounds | |
| CN103214449A (en) | Chloro benzophenone compound and preparation method and application thereof | |
| CN102329829B (en) | Method for converting daidzein into 8-hydroxydaidzein by utilizing penicillium | |
| CN102337308A (en) | Method for converting bergenin into special nitrogenous derivative by using penicillium | |
| CN102452916B (en) | New aromatic polyketones, extraction method and application thereof | |
| CN108342325B (en) | A kind of anthraquinone analog compound and its preparation method and application in Cordyceps cicadae source | |
| CN105837590A (en) | Compound with anti-Candida albicans activity, preparation method and application thereof | |
| CN103755785A (en) | Novel tetrapolypeptide compound and preparation method thereof | |
| CN109503623B (en) | Guanactastane compound, preparation method thereof and application thereof in preparation of antibacterial drugs | |
| CN107973803A (en) | A kind of seven yuan of lactone benzofuran derivs and its preparation method and application | |
| CN103275885A (en) | Streptomycete and its application in production of compounds having antibiotic effect | |
| CN107935819B (en) | Polyoxy-substituted cyclohexene derivative and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20150429 Termination date: 20160819 |